Annual meeting of the CARE 1 metastatic 1st line RCC study which is open in France 🇫🇷 and will open in 🇬🇧 soon. Biomarker driven trial (PD-L1) of ipi/nivo vs VEGF/PD1 Laurence Albiges . The Barts team in Paris enjoying the sunshine !!

Presented by Rebecca Dent at #ESMOBreast24 w/ simultaneous publication in Annals of Oncology 1st results of Impassion132 showing no benefit of adding #atezoliyumab to 1st line CT in pts w/ advanced #TNBC relapsing <12months.
#AnnOnc #BreastCancer tinyurl.com/5n99udja

Bravo to Annals of Oncology, a high-impact important journal in our field, for synchronizing the publication of a negative trial. Amplifying our wins is only valuable if we also discuss when we come up short. #ESMOBreast24 Rebecca Dent

🎧 Catch this Uromigos episode (@tompowles1, Brian Rini, MD) on side effects in patients with #metastatic hormone-sensitive #ProstateCancer .

👉 Featuring: Christopher Sweeney, MBBS, Matthew A. Smith, ONCODOC, and Dr. Lisa Horvath

👂 Listen Now: buff.ly/4bVmLh9

Uromigos

Very happy to chat to Uromigos about The Lancet Commission on Prostate Cancer. The ICR Listen now! open.spotify.com/episode/4KTac6…

Supercharged for the next #Uromigos meeting where we will defend our rights to the cup! ⁦Sumanta K. Pal, MD, FASCO⁩ ⁦Petros Grivas⁩ ⁦Uromigos⁩

Tom Powles Incredibly important trial, not only for melanoma but for all cancers using (or testing) peri-operative IO. Excited to see the results of this extraordinary accomplishment! Christian Blank Matt Galsky

The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary #ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung ascopubs.org/doi/10.1200/JC…

“The TIME Magazine 100 List for Healthcare? That’s cool & all, and I’m happy for Tom Powles, but I personally have always been after this shiny piece of metal …”

Behold — the Uromigos cup.

#UromigosLive24
#TeamLA : Tanya Dorff Petros Grivas
Uromigos.org

In Annals of Oncology, results of translational analyses studying the predictive and prognostic values of molecular subtypes & genomic alterations 🧬 in the MITO END-3 trial investigating the addition of Avelumab to chemo in metastatic endometrial cancer

annalsofoncology.org/article/S0923-…

Just in JAMA Network Open 👉Our paper on treatment trends and attrition rates for advanced #bladdercancer in the US👉2/3rd of patients did not receive even 2nd-line Rx. Grateful for mentorship by Umang Swami Neeraj Agarwal, MD, FASCO. Link👉 bit.ly/3UHwBgv GU Cancer Research Program @HuntsmanCancer OncoAlert

We are so excited to have the @uromigos back for kidney cancer board review & 2024 updates

First up with Localized RCC discussing risk factors, who needs genetic testing, who qualifies for adjuvant therapy…& who’s a faster swimmer btw Brian Rini, MD & Tom Powles

Silke Gillessen summaries the #APCCC meeting in Lugano on our most recent podcast podcasters.spotify.com/pod/show/the-u…

Which team will win the highly coveted Uromigos #UromigosCup competition to be invited to the #UromigosLive2024 meeting?
👇👇
Sumanta K. Pal, MD, FASCO Petros Grivas Tanya Dorff Neeraj Agarwal, MD, FASCO Toni Choueiri, MD Tian Zhang, MD, MHS

“So I’m backstage with Taylor, and Travis comes up to me and is like - ‘How does it feel to win the Uromigos cup?’”

#UromigosLive24 #SuperbowlOfOncology
#TeamLA : Tanya Dorff Petros Grivas

It has been a fantastic Advanced Prostate Cancer Consensus Conference meeting. Already looking forward to APCCC 2026!

Biomarker data from adjuvant ipi/nivo vs placebo study in renal cancer shows circulating Kidney injury marker-1(KIM-1), which is over expressed & prognostic in RCC #AACR24 , maybe important (along with PD-L1) in response to ipi/nivo. Patient selection for adjuvant IO is important

Check out our APCCC podcasts with Jason Efstathiou and Piet Ost discuss the data for and against adjuvant radiotherapy. podcasters.spotify.com/pod/show/the-u…

APCCC debate with Thomas Zilli and Pierre Blanchard covering radiation therapy for metastatic disease from Lugano. Thanks to Neeraj Agarwal, MD, FASCO for help with the tweet. #APCCC2024 OncoAlert . t.ly/D7N0_